NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed therapeutics.  The Company’s proprietary NovaMist™ technology enables rapid delivery of drugs into the bloodstream, which may result in faster onset of action and potential patient benefits in compliance, convenience and safety.  NovaDel’s most advanced candidates target angina, insomnia, and nausea.

By focusing its proprietary delivery technology on proven pharmaceuticals, NovaDel leverages existing safety and efficacy data to manage risk in the development and registration process. Our business strategy is to develop products and enter into value-generating partnerships for commercialization.

NovaDel is headquartered in Flemington, NJ.  Its common shares trade on the OTC Bulletin Board under the symbol:  NVDL.